

Experiment Number: 88073-03
Test Type: 90-DAY
Route: GAVAGE
Species/Strain: Mouse/B6C3F1

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: 2',3'-Dideoxycytidine

CAS Number: 7481-89-2

Date Report Requested: 10/22/2014

Time Report Requested: 02:46:44

First Dose M/F: NA / NA

Lab: SRI

C Number:	C88073B
Lock Date:	02/05/1993
Cage Range:	All
Date Range:	All
Reasons For Removal:	All
Removal Date Range:	All
Treatment Groups:	All
Study Gender:	Female
PWG Approval Date	NONE

Experiment Number: 88073-03

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: Mouse/B6C3F1

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: 2',3'-Dideoxycytidine

CAS Number: 7481-89-2

Date Report Requested: 10/22/2014

Time Report Requested: 02:46:44

First Dose M/F: NA / NA

Lab: SRI

B6C3F1 Mouse FEMALE	VEHICLE CONTROL	500 MG/KG	1000 MG/KG
Disposition Summary			
Animals Initially In Study	50	50	50
Early Deaths			
Moribund Sacrifice			3
Natural Death			3
Survivors			
Terminal Sacrifice	50	50	44
Animals Examined Microscopically	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(48)
Gallbladder	(48)	(49)	(49)
Lymphoma Malignant			4 (8%)
Intestine Large, Cecum	(50)	(50)	(50)
Lymphoma Malignant			2 (4%)
Intestine Large, Colon	(50)	(49)	(50)
Lymphoma Malignant			2 (4%)
Intestine Large, Rectum	(50)	(50)	(50)
Intestine Small, Duodenum	(49)	(49)	(48)
Lymphoma Malignant			1 (2%)
Intestine Small, Ileum	(49)	(48)	(47)
Lymphoma Malignant			2 (4%)
Intestine Small, Jejunum	(47)	(50)	(50)
Liver	(50)	(50)	(50)
Lymphoma Malignant			8 (16%)
Mesentery	(1)	(0)	(0)
Pancreas	(50)	(50)	(50)
Lymphoma Malignant			3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 88073-03

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: Mouse/B6C3F1

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: 2',3'-Dideoxycytidine

CAS Number: 7481-89-2

Date Report Requested: 10/22/2014

Time Report Requested: 02:46:44

First Dose M/F: NA / NA

Lab: SRI

B6C3F1 Mouse FEMALE	VEHICLE CONTROL	500 MG/KG	1000 MG/KG
Salivary Glands	(50)	(50)	(50)
Lymphoma Malignant			2 (4%)
Stomach, Forestomach	(50)	(50)	(50)
Lymphoma Malignant			1 (2%)
Stomach, Glandular	(50)	(50)	(50)
Lymphoma Malignant			3 (6%)
CARDIOVASCULAR SYSTEM			
Blood Vessel	(50)	(50)	(50)
Heart	(50)	(50)	(50)
Lymphoma Malignant			1 (2%)
ENDOCRINE SYSTEM			
Adrenal Cortex	(50)	(50)	(50)
Lymphoma Malignant			2 (4%)
Adrenal Medulla	(50)	(50)	(50)
Lymphoma Malignant			1 (2%)
Islets, Pancreatic	(50)	(50)	(50)
Parathyroid Gland	(47)	(47)	(45)
Pituitary Gland	(47)	(50)	(48)
Lymphoma Malignant			6 (13%)
Thyroid Gland	(50)	(50)	(50)
Lymphoma Malignant			1 (2%)
GENERAL BODY SYSTEM			
None			
GENITAL SYSTEM			
Clitoral Gland	(50)	(50)	(50)
Ovary	(50)	(50)	(50)
Lymphoma Malignant			6 (12%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 88073-03

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: Mouse/B6C3F1

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: 2',3'-Dideoxycytidine

CAS Number: 7481-89-2

Date Report Requested: 10/22/2014

Time Report Requested: 02:46:44

First Dose M/F: NA / NA

Lab: SRI

B6C3F1 Mouse FEMALE	VEHICLE CONTROL	500 MG/KG	1000 MG/KG
Lymphoma Malignant			6 (12%)
Uterus	(50)	(50)	(50)
Lymphoma Malignant			6 (12%)
Polyp Stromal	1 (2%)		3 (6%)
HEMATOPOIETIC SYSTEM			
Bone Marrow	(50)	(50)	(50)
Lymphoma Malignant			7 (14%)
Lymph Node	(0)	(0)	(5)
Deep Cervical, Lymphoma Malignant			1 (20%)
Iliac, Lymphoma Malignant			5 (100%)
Inguinal, Lymphoma Malignant			2 (40%)
Lymphoma Malignant			3 (60%)
Mediastinal, Lymphoma Malignant			1 (20%)
Pancreatic, Lymphoma Malignant			1 (20%)
Renal, Lymphoma Malignant			5 (100%)
Lymph Node, Mandibular	(49)	(49)	(47)
Lymphoma Malignant			7 (15%)
Lymph Node, Mesenteric	(49)	(50)	(47)
Lymphoma Malignant			7 (15%)
Spleen	(50)	(50)	(50)
Lymphoma Malignant			8 (16%)
Thymus	(49)	(49)	(47)
Lymphoma Malignant		3 (6%)	15 (32%)
INTEGUMENTARY SYSTEM			
Mammary Gland	(50)	(50)	(49)
Skin	(50)	(50)	(50)
MUSCULOSKELETAL SYSTEM			

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 88073-03

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: Mouse/B6C3F1

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: 2',3'-Dideoxycytidine

CAS Number: 7481-89-2

Date Report Requested: 10/22/2014

Time Report Requested: 02:46:44

First Dose M/F: NA / NA

Lab: SRI

B6C3F1 Mouse FEMALE	VEHICLE CONTROL	500 MG/KG	1000 MG/KG
Bone	(50)	(50)	(50)
Skeletal Muscle	(0)	(0)	(1)
Lymphoma Malignant			1 (100%)
NERVOUS SYSTEM			
Brain	(50)	(50)	(50)
Lymphoma Malignant			3 (6%)
Peripheral Nerve	(0)	(1)	(0)
Spinal Cord	(0)	(1)	(0)
RESPIRATORY SYSTEM			
Lung	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	1 (2%)		
Lymphoma Malignant			8 (16%)
Nose	(50)	(50)	(50)
Lymphoma Malignant			4 (8%)
Trachea	(50)	(50)	(50)
SPECIAL SENSES SYSTEM			
Ear	(0)	(1)	(0)
URINARY SYSTEM			
Kidney	(50)	(50)	(50)
Lymphoma Malignant			6 (12%)
Urinary Bladder	(49)	(50)	(50)
Lymphoma Malignant			3 (6%)
SYSTEMIC LESIONS			
Multiple Organ	*(50)	*(50)	*(50)
Lymphoma Malignant		3 (6%)	15 (30%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 88073-03

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: Mouse/B6C3F1

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: 2',3'-Dideoxycytidine

CAS Number: 7481-89-2

Date Report Requested: 10/22/2014

Time Report Requested: 02:46:44

First Dose M/F: NA / NA

Lab: SRI

B6C3F1 Mouse FEMALE	VEHICLE CONTROL	500 MG/KG	1000 MG/KG
Tumor Summary for FEMALE			
Total Animals with Primary Neoplasms (b)	2	3	17
Total Primary Neoplasms	2	3	18
Total Animals with Benign Neoplasms	2		3
Total Benign Neoplasms	2		3
Total Animals with Malignant Neoplasms		3	15
Total Malignant Neoplasms		3	15
Total Animals with Metastatic Neoplasms			
Total Metastatic Neoplasms			
Total Animals with Malignant Neoplasms Uncertain Primary Site			
Total Animals with Neoplasms Uncertain - Benign or Malignant			
Total Uncertain Neoplasms			

**** END OF REPORT ****

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically